Dyslipidemia: role in multifactorial management of type 2 diabetes mellitus
AbstractAccording to the World Health Organization, cardiovascular diseases are considered the leading cause of death worldwide. Most patients with diabetes mellitus have a high and very high risk of developing cardiovascular complications, and the target values correspond to LDL cholesterol levels of 1.8 and 1.4 mmol/l. According to the results of a large improve-it study, it was revealed that ezetimibe can be used as a second-line drug in combination with statins when statin monotherapy does not allow achieving the target level even when prescribed in maximum doses, as well as when statins are intolerant or there are contraindications to their use.
Keywords: dyslipidemia; diabetes mellitus; dyslipidemia therapy
Funding. The study had no sponsor support.
Conflict of interest. The author declares no conflict of interest.
For citation: Grigorieva M.A. Dyslipidemia: role in multifactorial management of type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2024; 13 (2): 87–8. DOI: https://doi.org/10.33029/2304-9529-2024-13-2-87-88 (in Russian)